ESR1 and breast cancer: The down regulation of NLRP3 inflammasome by Raloxifene, a selective estrogen receptor (ER) modulator, was also reported in relation to the inhibition of BC growth, demonstrating its involvement during cancerogenesis and its functional connection with hormone status [13].